LOGO
LOGO

Corporate News

Charles River Q4 Results Top Estimates, Sees FY23 Earnings Below Market; Stock Down In Premarket

By RTTNews Staff Writer   ✉   | Published:   | Follow Us On Google News
rttnewslogo20mar2024

Charles River Laboratories International, Inc. (CRL) reported Wednesday that its fourth-quarter profit and revenues climbed from last year, above market estimates. Looking ahead for fiscal 2023, the company issued weak earnings outlook, below market, despite higher revenue view.

In pre-market activity on the NYSE, Charles River Labs shares were losing around 9 percent to trade at $222.

The fourth-quarter net income attributable to shareholders was $187.41 million, an increase of 36.2 percent from $137.58 million last year.

Earnings per share were $3.65, up 36.7 percent from $2.67 for the fourth quarter of 2021. The earnings results were primarily driven by a gain on the sale of the Avian Vaccine business.

Adjusted net income was $152.9 million, compared to $128.4 million last year. Adjusted earnings per share were $2.98, compared to $2.49 a year ago.

On average, 14 analysts polled by Thomson Reuters expected earnings of $2.75 per share for the quarter. Analysts' estimates typically exclude special items.

For the quarter, revenue was $1.10 billion, an increase of 21.5 percent from $905.05 million in the fourth quarter of 2021. Analysts estimated revenues of $1.04 billion for the quarter.

Looking ahead for fiscal 2023, Charles River projects earnings in the range of $7.40 to $8.60 per share, and adjusted earnings in the range of $9.70 to $10.90 per share. The Street is looking for earnings of $11.37 per share for the year.

In fiscal 2022, earnings were $9.48 per share and adjusted earnings were $11.12 per share.

Earnings per share in 2023 will be affected by the impact of NHP supply constraints.

In addition, a higher tax rate, increased interest expense, and the impact of the divestiture of the Avian Vaccine business will reduce earnings per share by approximately $2.30 to $2.50 on a reported basis, and by around $1.20 to $1.40 on an adjusted basis.

For the new year, revenue growth is expected to be in the range of 1.5 percent to 4.5 percent on a reported basis, and 4.5 percent to 7.5 percent organically.

For more earnings news, earnings calendar, and earnings for stocks, visit rttnews.com.

For comments and feedback contact: editorial@rttnews.com

Business News

Get Access to Premium Stock Alerts with RTT Biotech Investor.
Global Economics Weekly Update: April 13 – April 17, 2026

April 17, 2026 15:29 ET
The ongoing conflict in the Middle East continues to raise concerns for policymakers who worry about the impact of the supply shock and high energy prices on the real economy. Producer price data and various survey results on the housing market were the main news from the U.S. this week. In Europe, industrial production data for the euro area gained attention. GDP figures out of China and the policy move by the Singapore central bank were in focus in Asia.